Print    

Home Page / News and Events / Archived Releases ...

Archived Press Releases

Please either scroll down to view the complete list of prior years' press releases or click one of the years below to view that year's archive.

2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001

BioTrove Announces R&D Collaboration with Constellation Pharmaceuticals on Epigenetic Targets

Agilent Technologies, BioTrove to Streamline Drug Discovery Using High-Throughput Mass Spectrometry

BioTrove Announces Agreement with BD to Boost Drug Discovery Research Efficiency

BioTrove Opens European Stronghold and Names Leadership for Expansion

BioTrove Expands Customer Support, Corporate Presence With New West Coast Office

Applied Biosystems/MDS Analytical Technologies and BioTrove Team Up to Improve Drug Discovery with High-Throughput Mass Spectrometry Applications

BioTrove, Synchron Team Up for European Customer Solutions

BioTrove Combines Forces with OSI Pharmaceuticals to Enable Lead Discovery

BioTrove, Inc. Announces Filing of Registration Statement for Initial Public Offering

BioTrove Names New Division Vice President-General Managers.

2007

BioTrove Names Edward "Buzz" Sztukowski Senior Vice President and Chief Business Officer

BioTrove, Inc. CEO Albert Luderer to Present at Piper Jaffray Health Care Conference

BioTrove, Inc. Appoints Jeffrey C. Leathe as Chief Financial Officer

Agilent Technologies and BioTrove Sign Collaborative Marketing Agreement for Ultra-High-Throughput Mass Spectrometry Solution

BioTrove Launches Next-Generation Mass Spectrometry System, Enables Accelerated Drug Discovery Research

Albert Luderer to Present at Leerink Swann Life Science Tools Roundtable as Invited Speaker

BioTrove Reports Strong First Half

BioTrove Launches Enabling Drug-Drug Interaction Applications for RapdiFire Drug Discovery Platform

BioTrove, Inc. Appoints Gregory C. Critchfield, M.D. to Board of Directors

2006

BioTrove, Inc. Names Edward L. Erickson to Board of Directors

BioTrove, Inc. Names Albert A. Luderer, Ph.D., President and Chief Executive Officer

BioTrove Screens Two Million Samples Using RapidFire Lead Discovery, a Label Free High-Throughput Mass Spectrometry Platform for Intractable Drug Targets

BioTrove, Inc. to Webcast Presentation at Leerink Swann & Company Roundtable Discussion

BioTrove and Blue Sky Biotech Introduce Unique Screening Solution Portfolio for Challenging Drug Targets

BioTrove, Inc. Completes a $15 Million Financing Round

2005

BioTrove and Schering-Plough Research Institute Expand RapidFire Lead Discovery Collaboration

BioTrove and Sirtris Pharmaceuticals Expand RapidFire High Throughput Screening Relationship

BioTrove Screens One Million Samples in 12 Months Using Mass Spectrometry

2004

BioTrove, Inc. Appoints Alan Carter as Vice President of Worldwide Sales

BioTrove, Inc. Completed a $13.7 Million Round of Financing with the Closing of a Second Traunch of $2.8 Million

BioTrove’s Momentum Signs First Contract with Large Pharmaceutical Customer

BioTrove, Inc. Secures $10.9 Million to Continue the Development and Commericalization of Novel Nano-Scale Drug Discovery Solutions

2003

BioTrove, Inc. Names Robert H. Ellis as President and Chief Executive Officer. Colin Brenan, Ph.D., Becomes Chief Technology Officer.

BioTrove, Inc. Launches Momentum Technology Ultra High Throughput Mass Spectrometry System for Functional Assay Development

BioTrove Names Robert H. Ellis as Chief Operating Officer

BioTrove, Inc. Relocates Corporate Headquarters to Woburn, Massachusetts

2002

BioTrove Raises $5.25 Million in Venture Financing

BioTrove Announces Issuance of Patent for Nanoliter-Volume Assay Platform

2001

BioTrove Announces Advanced Technology Program Award from N.I.S.T. for Massively Parallel Screening

BioTrove, Inc. Announces Collaborative Agreement with Pfizer, Inc

 

BIOCIUS. Faster Answers.

RapidFire® technology is described in patent numbers 6,932,939, 6,812,030 7,100,460, 7,588,725,